Promoted Content

Promoted Content

X

Find

Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace

Market Place

Post Enquiry

Grow Your Pharma Business Digitally

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

All Data

Filters

refresh

×

FILTER DATA :

News Type

Company

Product Type

Deal Size

Upfront Payment

refresh

Product Type

Companies

Tiziana Life Sciences

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

Virtual Innovation Day

Participation Not Confirmed

Update your events

Tiziana Announces the FDA Allowed Treatment for a Secondary Progressive Multiple Sclerosis Patient for the Nasal Administration of Foralumab

Contact the Supplier

Lead Product(s): Foralumab

Therapeutic Area: Immunology Product Name: TZLS-401

Highest Development Status: Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 30, 2021

Details:

Due to Foralumab’s ability to affect systemic immunity through the epithelial lining of the nose, respiratory tract and gut, it is the first antibody that can be dosed nasally or orally.